Nebivolol Inhibits Superoxide Formation by NADPH Oxidase and Endothelial Dysfunction in Angiotensin II–Treated Rats
-
- Matthias Oelze
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Andreas Daiber
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Ralf P. Brandes
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Marcus Hortmann
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Philip Wenzel
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Ulrich Hink
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Eberhard Schulz
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Hanke Mollnau
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Alexandra von Sandersleben
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Andrei L. Kleschyov
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Alexander Mülsch
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Huige Li
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Ulrich Förstermann
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
-
- Thomas Münzel
- From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
Description
<jats:p> Nebivolol is a β <jats:sub>1</jats:sub> -receptor antagonist with vasodilator and antioxidant properties. Because the vascular NADPH oxidase is an important superoxide source, we studied the effect of nebivolol on endothelial function and NADPH oxidase activity and expression in the well-characterized model of angiotensin II–induced hypertension. Angiotensin II infusion (1 mg/kg per day for 7 days) caused endothelial dysfunction in male Wistar rats and increased vascular superoxide as detected by lucigenin-derived chemiluminescence, as well as dihydroethidine staining. Vascular NADPH oxidase activity, as well as expression at the mRNA and protein level, were markedly upregulated, as well as NOS III uncoupled, as evidenced by NO synthase III inhibitor experiments and dihydroethidine staining and by markedly decreased hemoglobin–NO concentrations. Treatment with the β-receptor blocker nebivolol but not metoprolol (10 mg/kg per day for each drug) normalized endothelial function, reduced superoxide formation, increased NO bioavailability, and inhibited upregulation of the activity and expression of the vascular NADPH oxidase, as well as membrane association of NADPH oxidase subunits (Rac1 and p67 <jats:sup>phox</jats:sup> ). In addition, NOS III uncoupling was prevented. In vitro treatment with nebivolol but not atenolol or metoprolol induced a dissociation of p67 <jats:sup>phox</jats:sup> and Rac1, as well as an inhibition of NADPH oxidase activity assessed in heart membranes from angiotensin II–infused animals, as well as in homogenates of Nox1 and cytosolic subunit–transfected and phorbol ester–stimulated HEK293 cells. These findings indicate that nebivolol interferes with the assembly of NADPH oxidase. Thus, inhibitory effects of this β-blocker on vascular NADPH oxidase may explain, at least in part, its beneficial effect on endothelial function in angiotensin II–induced hypertension. </jats:p>
Journal
-
- Hypertension
-
Hypertension 48 (4), 677-684, 2006-10
Ovid Technologies (Wolters Kluwer Health)
- Tweet
Details 詳細情報について
-
- CRID
- 1361418521060811648
-
- ISSN
- 15244563
- 0194911X
-
- Data Source
-
- Crossref